Bai Minghua

Bai Minghua

Auto-generated profile, based on publicly available information

Bai Minghua

Zhejiang Key Laboratory of Particle Radiotherapy Equipment , Hangzhou , Zhejiang , China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
FXFu Xinmo
Fu Xinmo
BMBai Minghua
Bai Minghua
QXQiu Xu
Qiu Xu
LWLi Weiwei
Li Weiwei
WLWang Lin
Wang Lin
JZJi Zhu
Ji Zhu
Background: Radiotherapy resistance limits colorectal cancer (CRC) treatment efficacy, with only 15%–20% of patients achieving a complete response. Validated biomarkers predicting treatment response and serving as therapeutic targets are critically needed. Methods: We performed integrative multiomics analysis of 200 CRC patients (GSE87211) with independent validation in 58 patients (GSE46862). Single‐cell RNA sequencing of 63,689 cells (GSE132465) determined cell‐type‐specific expression. Functional validation was conducted in radiotherapy‐resistant CRC cell lines through loss‐of‐function experiments including proliferation, migration/invasion, and radiosensitivity assays. Results: FKBP10 emerged as the only gene achieving statistical significance in both discovery (log2FC = 0.74, p = 0.0007) and validation (log2FC = 0.52, p = 0.032) cohorts among 48 radioresistance‐associated genes. Single‐cell profiling revealed that FKBP10 was predominantly expressed in cancer‐associated fibroblasts (CAFs, 51.5% of stromal cells), implicating CAF‐mediated stromal remodeling in resistance. FKBP10 knockdown significantly inhibited proliferation, colony formation (35%–40% reduction), migration (30%), and invasion (50%), while markedly enhancing radiosensitivity through increased DNA damage ( γ H2AX foci increased twofold, p < 0.01) and strand breaks (comet tail DNA: 22% → 43%, p < 0.01). Conclusions: This multiomics study establishes FKBP10 as a robust CAF‐derived biomarker and functional therapeutic target for radiotherapy resistance in CRC, providing a foundation for developing FKBP10‐targeted combination strategies for precision cancer treatment.